+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07847073

Comparing Rhopressa and Timolol Eye Drops Using Adaptive Optics OCT for Retinal Nerve Cell Protection in Adults with Open-Angle Glaucoma

Led by Brett King · Updated on 2026-10-28

13

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two FDA-approved eye drops, netarsudil Rhopressa and timolol, to see how well they protect nerve cells in the eyes of adults with open-angle glaucoma. This condition causes loss of retinal ganglion cells, which are important for vision. The study aims to find out if Rhopressa slows down or prevents this cell loss better than timolol while both lower eye pressure. This research is a Phase 4, randomized, double-masked crossover study. Participants will use both medications during the study, each for six months in a random order. One group will start with Rhopressa once daily in the evening for six months, then switch to timolol twice daily for the next six months. The other group will do the opposite. Eye exams and measurements will be taken at baseline, six months, and twelve months, including advanced imaging with adaptive optics optical coherence tomography AO-OCT to count nerve cells, standard OCT, tonometry to measure eye pressure, and visual field tests. Participants will attend six visits over twelve months for eye examinations and imaging. Researchers will track changes in nerve cell density, counts, and thickness of the ganglion cell layer to compare the effects of both eye drops. Safety and tolerance will also be monitored. The study helps understand how these treatments influence nerve cell protection in glaucoma over one year.

CONDITIONS

Brief Title

Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients

Research Team

B

Brett J King, OD, FAAO, Dipl AAO (Glaucoma)

K

Kaitlyn M Asher, CCRC, BS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here